Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 520 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Drug Resistance Clear all

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 14 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 46
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 27 more

Conditions: Refractory or Recurrent Solid Tumors, Acute Myelogenous Leukemia
Interventions: Cediranib, AZD2171, RECENTIN; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 18 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures, Epilepsy in Children, Epilepsy, Epilepsy, Tonic-Clonic
Interventions: STARSTIM device, Sham Device; Device
Lead sponsor: Neuroelectrics Corporation; Industry
Eligibility: 9 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 18
States / cities: Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more

Conditions: Epilepsy in Children, Epilepsy in Youth, Randomized Controlled Trial, Refractory Epilepsy, Diet Intervention
Interventions: Low Glutamate diet; Other
Lead sponsor: American University; Other
Eligibility: 2 Years to 21 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Kidney Neoplasms, Neoplasm Metastasis
Interventions: PSC 833, vinblastine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Small Cell Lung Cancer
Interventions: CBT-1, Placebo; Drug · Other
Lead sponsor: CBA Research; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Tuscon, Arizona

Conditions: Infections Resistant to Multiple Drugs, Bacterial Infections
Interventions: Standard of Care; Other
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 6,496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Treatment-Resistant Depression
Interventions: MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg, Placebo Subcutaneous Injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: Birmingham, Alabama • Oakland Park, Florida • Tampa, Florida

Conditions: Auditory Hallucinations, Schizophrenia
Interventions: Active tDCS, Sham tDCS; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma, Smoldering Multiple Myeloma
Interventions: Bone Marrow Biopsy, Dexamethasone, Lenalidomide, Pomalidomide; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more

Conditions: Metastatic Castration Resistant Prostate Cancer, Prostate Neoplasms
Interventions: enzalutamide, CRLX101; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Temporal Lobe Epilepsy (TLE), Drug Resistant Epilepsy, Sleep
Interventions: Non-invasive Temporal Interference (TI) Stimulation Targeting Bilateral Hippocampi; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glucose Control, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Precision Medicine, Nutrition
Interventions: Premeal almond ingestion; Dietary Supplement
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 25 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Metabolism
Interventions: Blood draw; Procedure
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents, Analgesics, Peripheral Nervous System Agents, Physiological Effects of Drugs, Anesthetics, Dissociative, Anesthetics, General, Anesthetics, Central Nervous System Depressants, Excitatory Amino Acid Antagonists, Excitatory Amino Acid Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Ketamine, Depression, Unipolar, Depressive Symptoms, Treatment Resistant Depression, Major Depressive Disorder, Depression, Bipolar
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: E. Coli Infection, Multi-antibiotic Resistance
Interventions: Not listed
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes, Schizophrenia, Insulin Resistance, Cognitive Impairment
Interventions: Pioglitazone, Life style diet group, Placebo; Drug · Behavioral · Other
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus, Metabolic Syndrome, Obesity, Hypertension,Essential, Hyperlipidemias, Cardiovascular Diseases, Kidney Disease, Chronic
Interventions: Lifestyle Medicine Program, Medically Tailored Groceries; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Advanced Solid Tumor, Adult Solid Tumor, Adult Disease, Cancer, NSCLC, EGFR, KRAS G12C, Squamous Cell Lung Cancer
Interventions: TT125-802; Drug
Lead sponsor: TOLREMO therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Nashville, Tennessee • Fairfax, Virginia

Conditions: Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma
Interventions: Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab; Drug
Lead sponsor: Tempest Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 11
States / cities: San Francisco, California • Miami, Florida • Baltimore, Maryland + 7 more

Conditions: Drug Resistant Partial Onset Seizure
Interventions: ganaxolone, Placebo; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 25 more

Conditions: Type 2 Diabetes Mellitus, Obesity
Interventions: Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention; Procedure · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 25 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Interventions: Opevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate, Prednisone acetate, Enzalutamide; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 63
States / cities: Tucson, Arizona • Irvine, California • Los Angeles, California + 56 more

Conditions: Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS), Ovarian Cancer, Renal Cell Carcinoma (RCC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions: NZV930, PDR001, NIR178; Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Tampa, Florida • Houston, Texas

Search by objective public record fields.

A Comparison of Two Tests for Anti-HIV Drug Resistance

AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia

Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy

The Potential of a Low Glutamate Diet as a Treatment for Pediatric Epilepsy

A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer

A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer

Multi-Drug Resistant Organism Network

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

Non-Invasive Brain Stimulation for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

Overnight TI in TLE

Eating Almonds Before a Meal to Control Blood Sugar

Effect of Genetics on Metabolism of Efavirenz

Natural History of Depression, Bipolar Disorder and Suicide Risk

Perinatal Transmission of MDR Bacteria

Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia

Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.